tbuckley/cabot-search huggingface dataset:
Automated Digital Morphometry of Peripheral Blood Smears Detects Both Infrequent Events and Cellular Population Patterns in Myelodysplastic Syndrome
Authors: Ben Zion Katz, Shahar Karni, Hadar Shimoni, Amit Natan, Amir Shaham, Dan Benisty, Olga Pozdnyakova, Merav Barzilai, Moshe Mittelman, Irit Avivi
Journal: Blood (2021)
Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy
Authors: Jason Valent, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Sherry Fada, Michael Spector, Kathleen Stefunek, Heather Staley, Kristen Schlueter, Christy J. Samaras, Faiz Anwer, Jack Khouri, Jeffrey A. Zonder, Michaela Liedtke, Susan B. Sobolov
Journal: Blood (2021)
Pollution and the Heart
Authors: Sanjay Rajagopalan, Philip J. Landrigan
Journal: New England Journal of Medicine (2021)

ardiovascular diseases are the world's leading cause of disability and death.Such diseases were responsible in 2019 for an estimated 18.6 million deaths globally and 957,000 deaths in the United States. 1,2reat gains have been made in reducing the incidence of cardiovascular disease and related mortality in high-income countries.Identification of risk factors such as tobacco use, hypertension, dyslipidemia, physical inactivity, and diabetes in large, prospective, multiyear epidemiologic studies has been key.Recognition of these risk factors has increased awareness of cardiovascular diseases, enhanced early detection, and guided treatment and prevention.These advances have contributed to more than a 50% decline in mortality from cardiovascular disease in the United States since 1950. 3ollution -unwanted material released into the environment by human activity -is another important yet often overlooked risk factor for cardiovascular disease (Fig. 1). 4 The Global Burden of Disease (GBD) study estimates that pollution was responsible for 9 million deaths worldwide in 2019, 61.9% of which were due to cardiovascular disease, including ischemic heart disease (31.7%) and stroke (27.7%) (Fig. 2A). 1 These numbers, large as they are, almost certainly undercount the full contribution of pollution to the global burden of cardiovascular disease because they are based on only a subset of environmental risk factors. 4ntil now, pollution reduction has received scant attention in programs for cardiovascular disease control and has been largely absent from guidelines regarding the prevention of cardiovascular diseases, which have focused almost exclusively on individual behavioral and metabolic risk factors. 5This is an important omission, since incorporation of pollution reduction into cardiovascular disease prevention could save millions of lives.In this review, we summarize current evidence linking pollution to cardiovascular disease and suggest evidence-based strategies for disease prevention.We discuss strategies for reducing exposure to pollution in individual persons but argue that lasting prevention of pollution-related cardiovascular disease can be achieved only through government-supported interventions on a societal scale that control pollution at its source and encourage a rapid transition to clean energy.We note that these actions will also slow the pace of climate change and will thus produce a double benefit.Only through a multipronged strategy that combines pollution prevention with control of individual risk factors can the global epidemic of cardiovascular disease be contained. A ir Pollu tionAir pollution is a complex mixture that varies in concentration and composition according to time and place and is greatly influenced by weather. 5,6It includes particulate and gaseous primary pollutants such as nitrogen oxides (NO x ), sulfur dioxide, and carbon monoxide, which are released directly into the atmosphere, as
Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice
Authors: Liye Zhong, Yongqiang Wei, Baohong Ping, Xin Li, Hongling Peng, Yongqain Li, Yuyang Tian, Zelin Liu, Jun Luo, Yongzhong Su, Haifei Chen, Yanjuan He, Hongliang Li, Congming Wu, Zhiqiang Sun, Keqian Shi, Xiaoliang Li, Qing Zhang, Guoyu Hu, Gang Huang, Zhenqian Huang, Weida Wang, Zhongjun Xia
Journal: Blood (2021)
Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis
Authors: Alienor Campredon, Enzo Battistella, Clémence Martin, Isabelle Durieu, Laurent Mely, Christophe Marguet, Chantal Belleguic, Marlène Murris-Espin, Raphaël Chiron, Annlyse Fanton, Stéphanie Bui, Martine Reynaud-Gaubert, Philippe Reix, Trieu-Nghi Hoang-Thi, Maria Vakalopoulou, Marie-Pierre Revel, Jennifer Da Silva, Pierre-Régis Burgel, Guillaume Chassagnon
Journal: European Respiratory Journal (2021)

Objectives Lumacaftor-ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator known to improve clinical status in people with cystic fibrosis (CF). This study aimed to assess lung structural changes after one year of lumacaftor-ivacaftor treatment, and to use unsupervised machine learning to identify morphological phenotypes of lung disease that are associated with response to lumacaftor-ivacaftor. Methods Adolescents and adults with CF from the French multicenter real-world prospective observational study evaluating the first year of treatment with lumacaftor-ivacaftor were included if they had pretherapeutic and follow-up chest computed tomography (CT)-scans available. CT scans were visually scored using a modified Bhalla score. A k-mean clustering method was performed based on 120 radiomics features extracted from unenhanced pretherapeutic chest CT scans. Results A total of 283 patients were included. The Bhalla score significantly decreased after 1 year of lumacaftor-ivacaftor (−1.40±1.53 points compared with pretherapeutic CT; p&lt;0.001). This finding was related to a significant decrease in mucus plugging (−0.35±0.62 points; p&lt;0.001), bronchial wall thickening (−0.24±0.52 points; p&lt;0.001) and parenchymal consolidations (−0.23±0.51 points; p&lt;0.001). Cluster analysis identified 3 morphological clusters. Patients from cluster C were more likely to experience an increase in percent predicted forced expiratory volume in 1 sec (ppFEV 1 ) ≥5 under lumacaftor–ivacaftor than those in the other clusters (54% of responders versus 32% and 33%; p=0.01). Conclusion One year treatment with lumacaftor-ivacaftor was associated with a significant visual improvement of bronchial disease on chest CT. Radiomics features on pretherapeutic CT scan may help in predicting lung function response under lumacaftor-ivacaftor.
High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial
Authors: A. Vera de Jonge, Erik D. van Werkhoven, Marcel Nijland, Koen de Heer, Marjolein W.M. Van Der Poel, Yorick Sandberg, Clara Klerk, Esther E.E. Drees, Margaretha GM Roemer, Daphne de Jong, D. Michiel Pegtel, Bronno van der Holt, Tuna Mutis, Josée M Zijlstra, Marie José Kersten, Martine E.D Chamuleau
Journal: Blood (2021)
Realgar Indigo Formula Plus ATRA As Postremission Treatment in an Rral and Chemo-Free Model for High-Risk Acute Promyelocytic Leukemia Patients: A Prospective, Multicenter, Phase II Study
Authors: Hong-hu Zhu, Ya-fang Ma, Suning Chen, Ying Lu, Jiang Huang, Huai-Yu Wang, Xiaohua Xu, Bing-Shou Xie, Yinjun Lou, Jie Jin
Journal: Blood (2021)
IL-4 Mediated Upregulation of AMPK/SIRT1/PGC-1α Signalling Pathway Is Bypassed By Mitochondrial Complex I Downregulation By NAMPT Inhibition in Venetoclax and Ibrutinib Treated CLL Cells
Authors: Subir Roy Chowdhury, Cheryl Peltier, Eileen M. McMillan-Ward, Ryan Saleh, Tricia Choquette, Maxim Skorodinsky, Kira Peters, Edwin Nguyen, Amandeep Singh, Eric D. Bouchard, James B. Johnston, Aaron Marshall, James Thliveris, Spencer Bruce Gibson, Sara J. Israels, Versha Banerji
Journal: Blood (2021)
Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis
Authors: Jasmohan S Bajaj, Amirhossein Shamsaddini, Chathur Acharya, Andrew Fagan, Masoumeh Sikaroodi, Edith Gavis, Sara McGeorge, Alexander Khoruts, Michael Fuchs, Richard K Sterling, Hannah Lee, Patrick M Gillevet
Journal: Gut Microbes (2021)

Background & Aims Altered gut microbiota is associated with poor outcomes in cirrhosis, including infections and hepatic encephalopathy (HE). However, the role of bacterial virulence factors (VFs) is unclear. Aim: Define association of VFs with cirrhosis severity and infections, their linkage with outcomes, and impact of fecal microbiota transplant (FMT).Methods VF abundances were determined using metagenomic analysis in stools from controls and cirrhosis patients (compensated, HE-only, ascites-only, both and infected). Patients were followed for 90-day hospitalizations and 1-year death. Stool samples collected before/after a placebo-controlled FMT trial were also analyzed. Bacterial species and VFs for all species and selected pathogens (Escherichia, Klebsiella, Pseudomonas, Staphylococcus, Streptococcus, and Enterococcus spp) were compared between groups. Multi-variable analyses were performed for clinical biomarkers and VFs for outcome prediction. Changes in VFs pre/post-FMT and post-FMT/placebo were analyzed. Results: We included 233 subjects (40 controls, 43 compensated, 30 HE-only, 20 ascites-only, 70 both, and 30 infected). Decompensated patients, especially those with infections, had higher VFs coding for siderophores, biofilms, and adhesion factors versus the rest. Biofilm and adhesion VFs from Enterobacteriaceae and Enterococcus spp associated with death and hospitalizations independent of clinical factors regardless of when all VFs or selected pathogens were analyzed. FMT was associated with reduced VF post-FMT versus pre-FMT and post-placebo groups.Conclusions Virulence factors from multiple species focused on adhesion and biofilms increased with decompensation and infections, associated with death and hospitalizations independent of clinical factors, and were attenuated with FMT. Strategies focused on targeting multiple virulence factors could potentially impact outcomes in cirrhosis.Presentations Portions of this manuscript were an oral presentation in the virtual International Liver Congress 2021Abbreviations VF: virulence factors, HE: hepatic encephalopathy, FMT: Fecal microbiota transplant, PPI: proton pump inhibitors, LPS: lipopolysaccharides, VFDB: Virulence factor database, OTU: operational taxonomic units, SBP: spontaneous bacterial peritonitis, UTI: urinary tract infections, MRSA: methicillin resistant Staphylococcus aureus, VRE: vancomycin-resistant Enterococcus, MAAsLin2: Microbiome Multivariable Associations with Linear Models, LPS: lipopolysaccharides, AKI: acute kidney injury
A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Xingyu Cao, Guangna Liu, Jianping Zhang, Yanli Zhao, Hua Chen, Hongli Zheng, Wei Rui, Lemei Jia, Xueqiang Zhao, Xin Lin, Peihua Lu
Journal: Blood (2021)
Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience
Authors: Jorge Labrador, Miriam Saiz-Rodríguez, Maria Dunia De Miguel, Almudena De Laiglesia, Carlos Rodriguez, María Belén Vidriales, Manuel Pérez-Encinas, Maria Jose Sanchez, Rebeca Cuello, Alicia Roldán Pérez, Susana Vives, Gonzalo Benzo Callejo, Mercedes Colorado Araujo, María García-Fortes, Maria Jose Sayas, Carmen Olivier, Isabel Recio, Diego Conde, Alvaro Bienert Garcia, Maria Vahi, Carmen Muñoz García, Cristina Seri, Mar Tormo, Ferran Vall-llovera, Maria Angeles Foncillas, David Martínez-Cuadrón, Miguel A. Sanz, Pau Montesinos
Journal: Blood (2021)
Post-Transplant MRD Status and T Cell Chimerism Predict Outcomes in Patients Allografted for AML/MDS-a Prospective Analysis from the UK NCRI Figaro Trial
Authors: (Justin) Ching Ting Loke, Nicholas McCarthy, Aimee E Jackson, Shamyla Siddique, Andrea Hodgkinson, John Mason, Charles Crawley, Maria H Gilleece, Andy Peniket, Rachel Elizabeth Protheroe, Rahuman Salim, Eleni Tholouli, Keith Wilson, Georgia M. Andrew, Richard Dillon, Naeem Khan, Victoria Potter, Pramila Krishnamurthy, Charles Craddock, Sylvie D Freeman
Journal: Blood (2021)
Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study
Authors: Juliette Lambert, Jérôme Lambert, Emilie Lemasle, Magalie Joris, Sylvain Chantepie, Cecile Pautas, Xavier Thomas, Jean Valere Malfuson, Lauris Gastaud, Denis Caillot, Emmanuelle Tavernier, Pascal Turlure, Diana Carp, Celine Berthon, Olivier Legrand, Ambroise Marçais, Iona Vaida, Sarah Barbieux, Philippe Rousselot, Claude Gardin, Christine Terré, Nicolas Duployez, Claude Preudhomme, Karine Celli-Lebras, Sylvie Castaigne, Herve Dombret
Journal: Blood (2021)
Hexokinase domain-containing protein-1 in metabolic diseases and beyond
Authors: Joseph L. Zapater, Kristen R. Lednovich, Md. Wasim Khan, Carolina M. Pusec, Brian T. Layden
Journal: Trends in Endocrinology and Metabolism (2021)

Glucose phosphorylation by hexokinases (HKs) traps glucose in cells and facilitates its usage in metabolic processes dependent on cellular needs. HK domain-containing protein-1 (HKDC1) is a recently discovered protein with wide expression containing HK activity, first noted through a genome-wide association study (GWAS) to be linked with gestational glucose homeostasis during pregnancy. Since then, HKDC1 has been observed to be expressed in many human tissues. Moreover, studies have shown that HKDC1 plays a role in glucose homeostasis by which it may affect the progression of many pathophysiological conditions such as gestational diabetes mellitus (GDM), nonalcoholic steatohepatitis (NASH), and cancer. Here, we review the key studies contributing to our current understanding of the roles of HKDC1 in human pathophysiological conditions and potential therapeutic interventions.
Screening of Chemically Distinct Lipid Nanoparticles In Vivo Using DNA Barcoding Technology Towards Effectively Delivering Messenger RNA to Hematopoietic Stem and Progenitor Cells
Authors: Cory Sago, Elizabeth Campbell, Brianna Lutz, Neeraj Patwardhan, Gregory Hamilton, Courtney Wong, Daniel Lee, Shayon Keating, Kathryn Murray, Manmohan Singh, Giuseppe Ciaramella
Journal: Blood (2021)
A Novel Prognostic Index for Patients with EBV-DLBCL NOS: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Authors: Brady E Beltran, Denisse Castro, Luis Villela, Efreen Montaño Figueroa, Ana Florencia Ramirez-Ibarguen, Myrna Candelaria, Guilherme Fleury Perini, Ana Carolina Oliver, Humberto Martinez-Cordero, Henry Idrobo, Rosa Oliday Rios, Fabiola Valvert, Sally Rose Paredes, Carolina Cristina Pellegrino, Yusaima Rodriguez, Francisco Lopez, Victoria Irigoin, Maria Gabriela De Galvez, Jorge J. Castillo, Bryan Valcarcel, Luis Malpica Castillo
Journal: Blood (2021)
COVID-19 Diagnosis and Its Impact on Thrombotic Risk in a Cohort of Patients Simultaneously Hospitalized Due to Acute Respiratory Distress Syndrome
Authors: Andréa Coy-Canguçu, Gisele Aparecida Locachevic, João Carlos Silva Mariolano, Kaio Henrique De Oliveira Soares, José Diogo Oliveira, Camila de Oliveira Vaz, Gislaine Vieira Damiani, Bruna Mazetto, Joyce Maria Annichino- Bizzacchi, Erich V De Paula, Fernanda Andrade Orsi
Journal: Blood (2021)
Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma
Authors: David T. Melnekoff, Yogita Ghodke-Puranik, Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, Robert Sebra, Sundar Jagannath, Alessandro Lagana, Samir Parekh
Journal: Blood (2021)
Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease
Authors: Sheila K Pierson, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick, Frits van Rhee, David C Fajgenbaum
Journal: Blood (2021)
The Pan-Clk/Dyrk Inhibitor Cirtuvivint (SM08502) Exposes Mechanistic Underpinnings of Alternative Splicing As a Therapeutic Vulnerability in Heme Malignancies
Authors: Carine Bossard, Elizabeth A. McMillan, Emily Creger, Brian Eastman, Chi-Ching Mak, Darrin M. Beaupre, Michael A. White
Journal: Blood (2021)
RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation
Authors: Urszula Pakulska, Marta Obacz, Kristina Goller, Michal Combik, Kinga Keska, Jan Zaucha, Ewa Zarzycka, Milena Mazan, Michal Mikula, Magdalena Cybulska, Anna Polak, Przemyslaw Juszczynski, Johan Flygare, Jun Chen, Krzysztof Brzozka, Marcus Järås, Katarzyna Dziedzic, Noemi Angelosanto, Setareh Shamsili, Tomasz Rzymski
Journal: Blood (2021)
<i>In vivo</i> microevolution of <i>Mycobacterium tuberculosis</i> and transient emergence of <i>atpE</i>_Ala63Pro mutation during treatment in a pre-XDR TB patient
Authors: Arash Ghodousi, Alamdar Hussain Rizvi, Faisal Masood Khanzada, Nasim Akhtar, Abdul Ghafoor, Alberto Trovato, Daniela Maria Cirillo, Sabira Tahseen
Journal: European Respiratory Journal (2021)

<b>This letter describes microevolution of a pre-XDR MTB strain isolated from a pulmonary TB patient over an 18-month exposure to BDQ. MDR-TB therapies with BDQ require a functional background regimen to prevent emergence of additional resistance.</b>https://bit.ly/3D05qT9
Favorable impact in hepatitis C–related mortality following free access to direct‐acting antivirals in Spain
Authors: Julieta Politi, Juan‐Miguel Guerras, Marta Donat, María J. Belza, Elena Ronda, Gregorio Barrio, Enrique Regidor
Journal: Hepatology (2021)

Abstract Background and Aims Free treatments for HCV infection with direct‐acting antivirals became widespread in Spain in April 2015. We aimed to test whether, after this intervention, there was a more favorable change in population mortality from HCV‐related than from non‐HCV‐related causes. Approach and Results Postintervention changes in mortality were assessed using uncontrolled before–after and single‐group interrupted time series designs. All residents in Spain during 2001–2018 were included. Various underlying death causes were analyzed: HCV infection; other HCV‐related outcomes (HCC, liver cirrhosis, and HIV disease); and non‐C hepatitis, other liver diseases, and nonhepatic causes as control outcomes. Changes in mortality after the intervention were first assessed by rate ratios (RRs) between the postintervention and preintervention age‐standardized mortality rates. Subsequently, using quasi‐Poisson segmented regression models, we estimated the annual percent change (APC) in mortality rate in the postintervention and preintervention periods. All mortality rates were lower during the postintervention period, although RRs were much lower for HCV (0.53; 95% CI, 0.51–0.56) and HIV disease than other causes. After the intervention, there was a great acceleration of the downward mortality trend from HCV, whose APC went from −3.2% (95% CI, −3.6% to −2.8%) to −18.4% (95% CI, −20.6% to −16.3%). There were also significant accelerations in the downward trends in mortality from HCC and HIV disease, while they remained unchanged for cirrhosis and slowed or reversed for other causes. Conclusions These results suggest that the favorable changes in HCV‐related mortality observed for Spain after April 2015 are attributable to scaling up free treatment with direct‐acting antivirals and reinforce that HCV eradication is on the horizon.
Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing
Authors: Yumi Nakayama, Hsiling Chiu, Rama K. Narla, Arvind Shakya, Jim Gamez, Isobelle Wall, Despoina Papazoglou, Benedetta Apollonio, Alan G. Ramsay, Patrick Hagner, Anita K Gandhi
Journal: Blood (2021)
Compromised Host Stem Cell Competitiveness Affords Fanconi Stem Cell Engraftment in <i>C-Kit</i> Mutant Humanized Mice
Authors: Wei LIU, Yuanbin Song, Rana Gbyli, Esen Sefik, Giulia Biancon, Yimeng Gao, William Philbrick, Amisha Patel, Toma Tebaldi, Grzegorz Nalepa, Gary M. Kupfer, Richard Flavell, Stephanie Halene
Journal: Blood (2021)
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
Authors: Swagata Goswami, Rajeswaran Mani, Jessica Nunes, Chi-Ling Chiang, Kevan Zapolnik, Eileen Hu, Frank Frissora, Xiaokui Mo, Logan A. Walker, Pearlly Yan, Ralf Bundschuh, Larry Beaver, Raymond Devine, Yo-Ting Tsai, Ann Ventura, Zhiliang Xie, Min Chen, Rosa Lapalombella, Alison Walker, Alice Mims, Karilyn Larkin, Nicole Grieselhuber, Chad Bennett, Mitch Phelps, Erin Hertlein, Gregory Behbehani, Sumithira Vasu, John C. Byrd, Natarajan Muthusamy
Journal: Blood (2021)

Dysregulated cellular differentiation is a hallmark of acute leukemogenesis. Phosphatases are widely suppressed in cancers but have not been traditionally associated with differentiation. In this study, we found that the silencing of protein phosphatase 2A (PP2A) directly blocks differentiation in acute myeloid leukemia (AML). Gene expression and mass cytometric profiling revealed that PP2A activation modulates cell cycle and transcriptional regulators that program terminal myeloid differentiation. Using a novel pharmacological agent, OSU-2S, in parallel with genetic approaches, we discovered that PP2A enforced c-Myc and p21 dependent terminal differentiation, proliferation arrest, and apoptosis in AML. Finally, we demonstrated that PP2A activation decreased leukemia-initiating stem cells, increased leukemic blast maturation, and improved overall survival in murine Tet2-/-Flt3ITD/WT and human cell-line derived xenograft AML models in vivo. Our findings identify the PP2A/c-Myc/p21 axis as a critical regulator of the differentiation/proliferation switch in AML that can be therapeutically targeted in malignancies with dysregulated maturation fate.
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers
Authors: Adam Zayac, Daniel J Landsburg, Mitchell Hughes, Emily C. Ayers, Mark Girton, Marie Hu, Amy Beckman, Shaoying Li, L. Jeffrey Medeiros, Habibe Kurt, Jose Sandoval-Sus, M. Ali Ansari-Lari, Shalin K. Kothari, Anna Kress, Mina L. Xu, Pallawi Torka, Suchitra Sundaram, Stephen D. Smith, Kikkeri N Naresh, Yasmin Karimi, Narendranath Epperla, David A. Bond, Andrew M. Evens, Karan Pandya, Seema G Naik, Manali Kamdar, Brad Haverkos, Reem Karmali, Timothy Seijung Oh, Julie M. Vose, Heather Nutsch, Paul Rubinstein, Amina Chaudhry, Adam J. Olszewski
Journal: Blood (2021)